Functional Platinum Response Assays In Lung Cancer | 16408
Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In a recent, blinded clinical study on advanced lung cancer (stages IIIb and higher), the prognostic potential of an innovative,
cell-based ex vivo-assay was investigated with respect to the efficacy of platinum (Pt)-based chemotherapy. High Pt
sensitivity ex vivo was always associated with partial tumor remission. The onset of Pt resistance of the tumors was depicted
quantitatively in the tumor explants. Chemotherapy outcomes at various levels of Pt resistance in the explants correlated
plausibly with the additional cytostatic drugs used in combination with Pt, particularly pemetrexed. Ex vivo-assays for cellular
Pt response performed under conditions preventing photochemical artifacts should contribute to future optimizing of Pt-
based lung cancer chemotherapy.
Christof Granzow, M.D., is a Professor Emeritus of Biochemistry, University of Heidelberg, Germany. His group showed that the poor reproducibility of
chemoresponse assays due to riboflavin-mediated photochemical cell culture artifacts. At FLACOD GmbH, Heidelberg, he is concerned with novel protocols to
predict chemotherapy outcomes.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals